Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LYL1
REST API REST API
Homo sapiens
LYL1 is differentially expressed in 214 experiments: 85 organism parts: bone marrow, spleen, ... (83 more);, 198 disease states: normal, lung adenocarcinoma, ... (196 more);, 105 cell types 302 cell lines 22 compound treatments and 64 other conditions.
Synonyms bHLHa18
Orthologs Lyl1 (Rattus norvegicus)   Lyl1 (Mus musculus)   LYL1 (Bos taurus)   HLH3B (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, nucleus, positive regulation of transcription, DNA-dependent, B cell differentiation, definitive hemopoiesis, blood vessel maturation
InterPro Term HLH_DNA-bd
UniProt Accession P12980
Search EB-eye ENSG00000104903
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-MTAB-62, ... (26 experiments)

Factor Value U/D Experiments
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
HL-60
1
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-20081, E-GEOD-3529
Raji
2
E-MTAB-37, E-GEOD-96
SW480
1
2
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
296 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, E-GEOD-13987, ... (42 experiments)

Factor Value U/D Experiments
2
E-TABM-145, E-TABM-130
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD34+ progenitor cell
1
E-GEOD-96
neutrophil
1
E-GEOD-12662
T-cell
1
E-GEOD-10820
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-TABM-26, E-MTAB-62, ... (41 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
3
E-MTAB-37, E-GEOD-96, E-MTAB-62
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
prostate carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-96, E-TABM-26
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
colon carcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-MTAB-37, E-MTAB-62
192 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5824, E-GEOD-3720, E-TABM-868, E-GEOD-5099, ... (18 experiments)

Factor Value U/D Experiments
none
2
6
E-TABM-868, E-MEXP-1958, E-GEOD-2649, E-MEXP-1230, E-GEOD-995, ... (8 experiments)
control
29
2
E-GEOD-995, E-GEOD-5339
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
saline
1
E-GEOD-3026
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
16 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-21138, E-GEOD-19665, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-17385

Genotype
studied in E-GEOD-1923, E-GEOD-22593, E-TABM-321, E-TABM-868, E-GEOD-17347, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20504, E-GEOD-22278, E-GEOD-837, E-MEXP-2146 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-980

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1657, E-GEOD-17636, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837

Tumor grading
studied in E-GEOD-4271

Processing time: 0.567 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM